(15009138), K. S. R., (22687839), J. S. L., (15352499), M. M. M., (14850778), C. U. B., (22687842), I. R., (22687845), F. T., . . . (15027870), I. V. (2025). Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.
Chicagoスタイル(17版)引用形式(15009138), Kristoffer Staal Rohrberg, et al. Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors. 2025.
MLA(9版)引用形式(15009138), Kristoffer Staal Rohrberg, et al. Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors. 2025.
警告: この引用は必ずしも正確ではありません.